1.Mechanism by which miR-34a-5p/PLCD3 axis regulates osteoarthritis progression
Pu YING ; Yue XU ; Tong LU ; Yi XUE ; Yiming MIAO
Chinese Journal of Tissue Engineering Research 2024;33(33):5320-5325
		                        		
		                        			
		                        			BACKGROUND:Molecular mechanisms targeting the miRNA/mRNA axis to regulate osteoarthritis disease process have been studied.We identified the mRNA:phospholipase C delta 3(PLCD3)and its target miRNA(miR-34a-5p)with clinical predictive value through previous bioinformatics studies,while experiments to verify their specific roles and mechanisms in regulating osteoarthritis are still lacking. OBJECTIVE:To investigate the regulatory role and mechanism of miR-34a-5p/PLCD3 axis on osteoarthritis progression. METHODS:The synovium of 15 patients with knee osteoarthritis was selected as the osteoarthritis group,and the synovium of 15 young patients with internal fixation of patellar fracture caused by trauma during the same period was selected as the control group.The expression of PLCD3 and miR-34a-5p in the synovium was detected by real-time PCR.Human fibroblast like synovial cells-osteoarthritis(HFLS-OA)cells were treated by cell transfection and divided into miR-34a-5p mimic group,pCDH-PLCD3 group,miR-34a-5p mimic+pCDH-PLCD3 group,miR-34a-5p inhibitor group,si-PLCD3 group,and miR-34a-5p inhibitor+si-PLCD3 group.The relationship between PLCD3 and miR-34a-5p expression was detected by real-time PCR.The effects of HFLS-OA cell viability and cell migration in each group were detected by CCK-8 assay and cell scratch test.Western blot assay was used to detect the expression level of apoptosis marker protein.The expression of inflammatory factors was detected by ELISA. RESULTS AND CONCLUSION:(1)PLCD3 was a direct target of miR-34a-5p,and the expression levels of PLCD3 and miR-34a-5p were negatively correlated.(2)Upregulation of PLCD3 promoted proliferation of HFLS-OA cells and inhibited cell migration.The up-regulation of miR-34a-5p significantly inhibited the activity of HFLS-OA cells and enhanced cell migration.Overexpression of miR-34a-5p significantly increased the levels of Casp3 and Casp9 proteins in HFLS-OA cells,while overexpression of PLCD3 showed the opposite trend.(3)PLCD3 overexpression significantly increased the expression of interleukin 6 and tumor necrosis factor alpha in HFLS-OA cells,while miR-34a-5p mimics showed protective activity.(4)The miR-34a-5p/PLCD3 axis may affect the progression of osteoarthritis by regulating the inflammatory process or apoptosis of synovial cells.
		                        		
		                        		
		                        		
		                        	
2.Expression of PLCD3 mRNA in synovium of osteoarthritis and its relationship with immune cell infiltration
Pu YING ; Zhi ZHENG ; Yue XU ; Ye ZHOU ; Yufan GE ; Yi XUE ; Yiming MIAO
International Journal of Laboratory Medicine 2024;45(2):208-212
		                        		
		                        			
		                        			Objective To investigate the expression of PLCD3 mRNA in the synovium of osteoarthritis(OA)and its relationship with immune cell infiltration.Methods Based on the differentially expressed genes of OA found in the previous study,the expression of phospholipase Cδ3(PLCD3)mRNA was detected by col-lecting synovial samples from OA group and control group.CIBERSORT algorithm was used to analyze the infiltration pattern of immune cells in OA group and control group,and the correlation between PLCD3 and infiltrating immune cells was further analyzed.Results Compared with the control group,the relative expres-sion level of PLCD3 mRNA was significantly increased in synovial samples of OA group(P<0.05).The pro-portions of B cells naive,NK cells activated,M2 macrophages and mast cells activated in synovial tissues of OA group were relatively high(P<0.05).PLCD3 was positively correlated with the proportion of these four immune cells(P<0.05).Conclusion PLCD3 may be a key biomarker for the diagnosis of OA,which may be involved in the pathogenesis of OA by interacting with infiltrating immune cells.
		                        		
		                        		
		                        		
		                        	
3.Relationship between coagulation indicators and early stage prognosis in patients with acute respiratory distress syndrome
Xiaoer JIN ; Yufan PU ; Miao WANG ; Chunmeng XUE ; Qingbo LIAO ; Qi DING
Chongqing Medicine 2024;53(15):2296-2300,2307
		                        		
		                        			
		                        			Objective To investigate the relationship between coagulation indicators and early prognosis in patients with acute respiratory distress syndrome (ARDS).Methods The data of ARDS patients receiving the treatment in the intensive care unit (ICU) from 2008-2019 were selected from the Critical Care Medicine Open Database (MIMIC-Ⅳ V2.0 version) jointly published by MIT,Beth Israel Deaconess Medical Center,and Philips Medical,the data were categorized according to the severity of the patients' disease and the causes of lung damage.The coagulation indexes and 28 d mortality (m28d) rates were compared among different ARDS patients.The receiver operating characteristic (ROC) curve was drawn.The area under the curve was calculated to evaluate the predictive values of the related indicators.The univariate and multivariate logistic re-gression was adopted to analyze the risk factors affecting m28d in the patients with ARDS.Results Maximum prothrombin time (PTmax) in the patients with pulmonary origin ARDS was significantly lower than that in the patients without pulmonary origin ARDS,and the difference was statistically significant (P<0.05).PLTmin,PLTmax and Sequential Organ Failure Assessment (SOFA) score had statistical difference among dif-ferent severity degrees of ARDS patients (P<0.05).Minimum international normalized ratio (INRmin),maxi-mum international normalized ratio (INRmax),minimum prothrombin time (PTmin),PTmax,maximum activated partial thromboplastin time (APTTmax) and SOFA score had statistical differences between the survival group and death group (P<0.05).AUC of INRmin,INRmax,PTmin,PTmax and APTTmax were 0.607,0.624,0.610,0.620 and 0.648 respectively.The multivariate logistic regression analysis showed that APTTmax (OR=1.011,95%CI:1.001-1.022,P=0.029) was an independent risk factor for affecting m28d in the ARDS patients.Conclu-sion Plasma PLT levels in different severities of ARDS patients have the difference and APTTmax on the first day in ICU is an independent risk factor for affecting early prognosis in ARDS patients.
		                        		
		                        		
		                        		
		                        	
4.A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
Ting LIU ; Qing LI ; Zhen LIN ; Chunhua LIU ; Wei PU ; Shasha ZENG ; Jun LAI ; Xuebin CAI ; Lisha ZHANG ; Shuyang WANG ; Miao CHEN ; Wei CAO ; Hongfeng GOU ; Qing ZHU
Cancer Research and Treatment 2024;56(2):602-615
		                        		
		                        			 Purpose:
		                        			Patients with advanced biliary tract cancer (BTC) have a poor survival. We aim to evaluate the efficacy and safety of nab-paclitaxel plus gemcitabine and cisplatin regimen in Chinese advanced BTC patients. 
		                        		
		                        			Materials and Methods:
		                        			Eligible patients with locally advanced or metastatic BTC administrated intravenous 100 mg/m2 nab-paclitaxel, 800 mg/m2 gemcitabine, and 25 mg/m2 cisplatin every 3 weeks. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS) and adverse events, while exploratory endpoint was the association of biomarkers with efficacy. 
		                        		
		                        			Results:
		                        			After the median follow-up of 25.0 months, the median PFS and OS of 34 enrolled patients were 7.1 months (95% confidence interval [CI], 5.4 to 13.7) and 16.4 months (95% CI, 10.9 to 23.6), respectively. The most common treatment-related adverse events at ≥ 3 grade were neutropenia (26.5%) and leukopenia (26.5%). Survival analyses demonstrated that carcinoembryonic antigen (CEA) levels could monitor patients’ survival outcomes. A significant increase in the number of infiltrating CD4+ cells (p=0.008) and a decrease in programmed death-1–positive (PD-1+) cells (p=0.032) were observed in the response patients. 
		                        		
		                        			Conclusion
		                        			In advanced BTC patients, nab-paclitaxel plus gemcitabine and cisplatin regimen showed therapeutic potential. Potential prognostic factors of CEA levels, number of CD4+ cells and PD-1+ cells may help us maximize the efficacy benefit. 
		                        		
		                        		
		                        		
		                        	
5.Clinical observation of Jipei dilong ointment combined with diacerein in the treatment of knee osteoarthritis in the early and mid-term stage
Qiang ZHANG ; Yifa CAO ; Jianshan HU ; Pu LI ; Jing HU ; Yaoyu LU ; Jun SU ; Zicong LIANG ; Zhu YANG
China Pharmacy 2023;34(9):1099-1103
		                        		
		                        			
		                        			OBJECTIVE To investigate clinical efficacy and safety of Jipei dilong ointment combined with diacerein in the treatment of knee osteoarthritis (KOA) in the early and mid-term stage. METHODS Totally 100 KOA patients were randomly divided into control group and trial group, with 50 cases in each group. Control group received Diacerein capsules orally, 50 mg every time, bid. Trial group additionally received Jipei dilong ointment, once a day, on the basis of control group. Both groups had a treatment course of 4 weeks, and were followed up for 3 months after treatment. The clinical efficacy of 2 groups, visual analogue scale (VAS), Western Ontario and McMaster University osteoarthritis index (WOMAC) score, Lysholm scores before and after treatment, at 3-month follow-up after treatment were all observed; the levels of tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β), IL-6, superoxide dismutase (SOD), malondialdehyde (MDA), nitric oxide (NO), cartilage oligomeric matrix protein (COMP), matrix metalloproteinase-13 (MMP-13) and C-telopeptide of type Ⅱ collagen (CTX-Ⅱ) were detected in knee joint fluid. The incidence of adverse drug reactions was recorded. RESULTS After 4 weeks of treatment, total effective rate was 96.0% in trial group and 90.0% in control group, without statistical significance between 2 groups (P>0.05). At 3- 2019YFC1712500) month follow-up after treatment, total effective rate of trial group was 94.0%, and was higher than 62.0% of control group(P<0.05). After 4 weeks of treatment and at 3-month follow-up after treatment, VAS score, WOMAC score,the contents ofTNF-α, IL-1β, IL-6, MDA, NO, COMP, MMP-13 and CTX-Ⅱ in knee joint fluid of two groups were significantly lower than before; Lysholm score and SOD activity of knee joint fluid were significantly higher than before, and the trial group was significantly better than the control group during the same period (P<0.05). And there was no statistical significance in the incidence of adverse drug reactions between two groups(P>0.05). CONCLUSION For the treatment of KOA in early and mid- term stage, Jipei dilong ointment combined with diacerein relieve pain, improve knee function by inhibiting inflammatory reaction, reducing oxidative stress and inhibiting chondrocyte and matrix degradation, and have low incidence of adverse drug reactions.
		                        		
		                        		
		                        		
		                        	
6.Preliminary exploration on operation process for autologous ozonized blood transfusion
Jianjun WU ; Yan BAI ; Yanli BAI ; Zhanshan ZHA ; Jing CHEN ; Yahan FAN ; Jiwu GONG ; Shouyong HUN ; Hongbing LI ; Zhongjun LI ; Jiajin LIN ; Chunxia LIU ; Fenghua LIU ; Jiubo LIU ; Jingling LUO ; Xianjun MA ; Deying MENG ; Shijie MU ; Mei QIN ; Hui WANG ; Haiyan WANG ; Qiushi WANG ; Quanli WANG ; Xiaoning WANG ; Yongjun WANG ; Changsong WU ; Lin WU ; Jue XIE ; Pu XU ; Liying XU ; Mingchia YANG ; Yongtao YANG ; Yang YU ; Zebo YU ; Juan ZHANG ; Xiaoyu ZHOU ; Xuelian ZHOU ; Shuming ZHAO
Chinese Journal of Blood Transfusion 2023;36(2):95-100
		                        		
		                        			
		                        			Autologous ozonized blood transfusion(AOBT) is a therapy of re-transfusion of 100-200 mL of autologous blood after shaking and agitation with appropriate amount of oxygen-ozone in vitro. The oxidation of blood through the strong oxidation of ozone can enhance the non-specific immune response of the body, regulate the internal environment and promote health. This therapy has been increasingly applied in clinical practice, while no unified standard for the operation process in terms of ozone concentration, treatment frequency and treatment course had been established. This operation process of AOBT is primarily explored in order to standardize the operation process and ensure its safety and efficacy.
		                        		
		                        		
		                        		
		                        	
7.Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines,anti-PD-1 and poly I:C
Ping ZHU ; Shi-You LI ; Jin DING ; Zhou FEI ; Sheng-Nan SUN ; Zhao-Hui ZHENG ; Ding WEI ; Jun JIANG ; Jin-Lin MIAO ; San-Zhong LI ; Xing LUO ; Kui ZHANG ; Bin WANG ; Kun ZHANG ; Su PU ; Qian-Ting WANG ; Xin-Yue ZHANG ; Gao-Liu WEN ; Jun O.LIU ; Thomas-John AUGUST ; Huijie BIAN ; Zhi-Nan CHEN ; You-Wen HE
Journal of Pharmaceutical Analysis 2023;13(6):616-624
		                        		
		                        			
		                        			Glioblastoma(GBM)is a lethal cancer with limited therapeutic options.Dendritic cell(DC)-based cancer vaccines provide a promising approach for GBM treatment.Clinical studies suggest that other immu-notherapeutic agents may be combined with DC vaccines to further enhance antitumor activity.Here,we report a GBM case with combination immunotherapy consisting of DC vaccines,anti-programmed death-1(anti-PD-1)and poly I:C as well as the chemotherapeutic agent cyclophosphamide that was integrated with standard chemoradiation therapy,and the patient remained disease-free for 69 months.The patient received DC vaccines loaded with multiple forms of tumor antigens,including mRNA-tumor associated antigens(TAA),mRNA-neoantigens,and hypochlorous acid(HOCl)-oxidized tumor lysates.Furthermore,mRNA-TAAAs were modified with a novel TriVac technology that fuses TAAs with a destabilization domain and inserts TAAs into full-length lysosomal associated membrane protein-1 to enhance major histo-compatibility complex(MHC)class Ⅰ and Ⅱ antigen presentation.The treatment consisted of 42 DC cancer vaccine infusions,26 anti-PD-1 antibody nivolumab administrations and 126 poly I:C injections for DC infusions.The patient also received 28 doses of cyclophosphamide for depletion of regulatory T cells.No immunotherapy-related adverse events were observed during the treatment.Robust antitumor CD4+and CD8+T-cell responses were detected.The patient remains free of disease progression.This is the first case report on the combination of the above three agents to treat glioblastoma patients.Our results suggest that integrated combination immunotherapy is safe and feasible for long-term treatment in this patient.A large-scale trial to validate these findings is warranted.
		                        		
		                        		
		                        		
		                        	
8.Clinical and genotypic characteristics of 19 children with STXBP1-encephalopathy
Lina QI ; Haiming YAO ; Pu MIAO ; Jianhua FENG
China Modern Doctor 2023;61(35):23-26,53
		                        		
		                        			
		                        			Objective To summarize the clinical phenotype and gene mutation characteristics of early epileptic encephalopathy caused by STXBP1 gene mutation and the application of second-generation gene sequencing in etiological diagnosis.Methods Retrospective analysis of clinical characteristics,gene test results,treatment and efficacy of 19 children with epileptic encephalopathy with genetic diagnosis of STXBP1 gene mutation who were seen in the Department of Pediatrics of the Second Hospital of Zhejiang University School of Medicine from January 2017 to January 2021.Results The disease started within 1 month after birth in 15 children(78.9%).All 19 children had significant electro-encephalo gram(EEG)changes:13 cases of burst suppression(68.4%)and high arrhythmia in 12 cases(63.2%).A total of 18 pathogenic variants were detected in 19 children,all of them new,of which 7 loci have not been reported so far.Five children were diagnosed with Otahara syndrome,five with infantile spasms,and nine with an epileptic syndrome that could not be classified.At a follow-up of 6 months to 4 years and 5 months,1 case was discontinued,5 cases had complete remission of seizures,6 cases had partial remission,and 7 cases were ineffective.8 of the 12 children with seizure remission or control were treated effectively with combination levetiracetam,4 of the 6 children with spasms responded with the addition of vigabatrin,and 7 presented with drug refractory epilepsy.All 19 children had varying degrees of developmental delay.Conclusion Mental-motor retardation and recurrent seizures are the main,independent phenotypic features of STXBP1-encephalopathy,STXBP1 gene variants are predominantly de novo variants,second-generation gene sequencing diagnosis helps in the early diagnosis of STXBP1-encephalopathy,levetiracetam and aminocaproic acid may be partially effective in controlling seizures in STXBP1-encephalopathy,and ketogenic diet provides new ideas for early-onset epileptic encephalopathy treatment provides a new idea.
		                        		
		                        		
		                        		
		                        	
9.Enlightenment of international experience of organ donation related systematic multi-department collaboration to China
Jie ZHAO ; Feng HUO ; Hongtao ZHAO ; Miao PU
Organ Transplantation 2022;13(6):683-
		                        		
		                        			
		                        			Organ transplantation is an effective treatment for end-stage organ failure. The shortage of donors severely restricts the development of organ transplantation, which is also an unresolved challenge in the reform of organ transplantation in China. To alleviate the shortage of donors, western countries have established the working mechanism of systematic multi-department collaboration (SMDC), which has significantly elevated the level of organ donation by promoting systematic collaboration among relevant departments in all aspects of organ donation. At present, organ donation and transplantation in China have entered the new stage of high-quality development, whereas the level of organ donation remains to be further improved. In this article, the concept of SMDC, the procedures and departments related to SMDC, and the international experience of SMDC were illustrated. Besides, suggestions and proposals were delivered for implementing SMDC in China and constantly developing and modifying the Chinese model of organ donation catering to national conditions.
		                        		
		                        		
		                        		
		                        	
10.Early effect of extracorporeal membrane oxygenation and factors related to early outcome in adult patients with fulminant myocarditis.
Yuan Hang ZHOU ; Xi ZHAO ; Ying Ying GUO ; Jia Ming YANG ; Dong Pu DAI ; Zi Ao RUI ; Yang DU ; Shuo PANG ; Guang Rui MIAO ; Xiao Fang WANG ; Xiao Yan ZHAO ; Jian Zeng DONG
Chinese Journal of Cardiology 2022;50(3):270-276
		                        		
		                        			
		                        			Objective: To evaluate the efficacy within the first 24 h post extracorporeal membrane pulmonary oxygenation (ECMO) and the impact of early efficacy on the prognosis of adult patients with fulminant myocarditis (FM). Methods: This retrospective case analysis study included hospitalized patients (age≥18 years) who were diagnosed with fulminant myocarditis from November 2016 to May 2021 in the First Affiliated Hospital of Zhengzhou University. Patients were divided into survival or non-survival groups according to treatment outcomes. The age, sex, treatments, drug use, ECMO use, clinical and laboratory data (before and 24 h after the use of ECMO) were analyzed. The change rate of clinical and laboratory data after 24 h use of ECMO was calculated to find differences between two groups. Multivariate logistic regression was used to analyze the related factors with in-hospital death and complication between the two groups. Results: A total of 38 FM patients treated with ECMO were included. There were 23 cases (60.5%) in the survival group, aged (39.6±13.7) years, and 17 (73.9%) cases were female. The total ECMO time was (134.4±71.3)h. There were 15 cases (39.5%) in non-survival group, aged (40.0±15.8) years, and there were 12(80.0%) female, the ECMO time was (120.1±72.4) h in this group. The proportion of tracheal intubation and continuous renal replacement therapy in the survivor group and dosage of norepinephrine within 24 h after ECMO implantation were significantly less than in non-survival group (all P<0.05). There was no significant difference in all efficacy related biochemical indexes between two groups before ECMO use. The levels of lactic acid, procalcitonin, creatinine, alanine aminotransferase, aspartate aminotransferase, creatine kinase-MB, cardiac troponin I and N-terminal B-type natriuretic peptide prosoma were significantly less in survival group than in non-survival group at 24 h after the use of ECMO (all P<0.05). Results of multivariate logistic regression analysis showed that the higher 24 h change rate of creatinine (OR=0.587, 95%CI 0.349-0.986, P=0.044) and creatine kinase-MB (OR=0.177, 95%CI 0.037-0.841, P=0.029) were positively correlated with reduced risk of in-hospital mortality. The central hemorrhage and acute kidney injury in survival group were less than in non-survivor group (P<0.05). Conclusions: After 24 h early use of ECMO in FM patients, the improvement of various efficacy related biochemical test indexes in the survival group was better than that in the non-survival group. Faster reduction of creatine kinase-MB and creatinine values within 24 h ECMO use is positively correlated with reduced risk of in-hospital mortality in adult patients with FM.
		                        		
		                        		
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Extracorporeal Membrane Oxygenation/methods*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Hospital Mortality
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Myocarditis/therapy*
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Treatment Outcome
		                        			;
		                        		
		                        			Young Adult
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail